In vitro studies based on HER2+ breast cancer cell lines with either intrinsic or acquired resistance to trastuzumab, lapatinib or both trastuzumab and lapatinib have been performed to determine the role of ERα in the onset of resistance to HER2-targeted therapies [15]. Here, ESR1 is linked to breast cancer.